Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2020 in severe Alzheimer's disease (China, Phase III)
CTR20130225Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing E2020 (donepezil) tablet with Placebo tablet (2 arms). Primary endpoint: Change from baseline in SIB score at 24 weeks. Started Jul 2014; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20130225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130225.